- New studies will evaluate the effect of JARDIANCE for the treatment of chronic heart failure
- There are approximately 26 million people worldwide, and 5.7 million people in the U.S., suffering from chronic heart failure
- The studies build on results from the landmark EMPA-REG OUTCOME® trial
Only Manufacturer to Offer the Antibiotic in a Ready-to-Use Premixed Presentation
The U.S. Food and Drug Administration today approved Zepatier (elbasvir and grazoprevir) with or without ribavirin for the treatment of chronic hepatitis C virus (HCV) genotypes 1 and 4 infections in adult patients.
French pharmaceutical firm Sanofi and Germany-based Fraunhofer-Gesellschaft have formed a natural product center of excellence to speed up the discovery and development of new therapies to treat infectious diseases.
Neos Therapeutics, Inc, a pharmaceutical company with a late‐stage pipeline of innovative extended-release (XR) product candidates for the treatment of attention-deficit/hyperactivity disorder (ADHD) announced that the U.S. FDA approved Adzenys XR-ODT for the treatment of ADHD in patients six years and older.
AstraZeneca is making available preclinical data from over 50 of its medicines as part of the DREAM Challenge, an open innovation competition, to find the most synergistic drug combinations with the potential to treat cancer. Public release of a data set of this scale is unprecedented and is intended to help advance research into combination cancer therapy across the global scientific community.
Galena Biopharma and Dr. Reddy's Laboratories have entered into a strategic development and commercialization partnership on NeuVax (nelipepimut-S) in India.